TEVA PHARMACEUTICAL INDUSTRIES LTD 4

Eric A. Hughes received 52,744 Teva ordinary shares from RSU vesting and sold 25,578 shares (~$0.9M) on August 3, 2026, leaving him with 134,877 shares.

On August 3, 2026, Eric A. Hughes, Executive Vice President, Global R&D and Chief Medical Officer of Teva Pharmaceutical Industries Ltd., had 52,744 ordinary shares issued to him upon the vesting/settlement of an equivalent number of restricted share units, increasing his direct holdings to 160,455 shares before any sales. On the same day, pursuant to a pre-arranged Rule 10b5-1 trading plan, he sold 25,578 ordinary shares at a weighted average price of approximately $34.88 per share, generating proceeds of roughly $892,000, primarily to cover tax withholding obligations associated with the RSU vesting. After these transactions, Hughes directly owned 134,877 ordinary shares of Teva, representing an estimated stake value of about $4.68 million based on the recent trading price.

Filing Facts

CIK

818686

Ticker

TEVA

Form

4

Source Type

fda

Accession

0001193125-26-335012

Alert Tier

6